Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
SLV.WA
HoldUnloved QualitySelvita S.A. · Healthcare · Poland · $132M · Avg Vol: $134K/d
COMPANY DESCRIPTION
Selvita S.A. is a leading European contract research organization (CRO) providing multidisciplinary drug discovery and development services to global biotech and pharmaceutical companies. The company's competitive advantage stems from its highly skilled scientific workforce and state-of-the-art laboratory infrastructure in Poland and Croatia. It is a major integrated service provider in the global preclinical research market.
FINANCIAL SUMMARY (PLN)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | 360.7M | 346.7M | 342.0M | 364.2M | 0.3% | 359.4M | 357.9M | 395.6M | 4.2% |
| EPS (PLN) | 0.80 | 1.70 | 3.80 | -0.30 | 0.04 | -52.7% | -0.21 | — | — | — |
| Shares | — | 18.4M | 18.4M | 18.4M | 18.4M | -0.0% | 18.4M | — | — | — |
| Debt | — | 213.0M | 224.7M | 218.5M | 169.6M | -7.3% | 167.9M | — | — | — |
| Equity | — | 262.2M | 327.1M | 321.9M | 321.7M | 7.1% | — | — | — | — |
| Op CF | — | 75.4M | 79.0M | 64.1M | 73.3M | -1.0% | 72.2M | — | — | — |
| Inv CF | — | -79.8M | -65.2M | -36.9M | -8.7M | — | — | — | — | — |
| Fin CF | — | -5.7M | -31.0M | -57.3M | -62.9M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of SLV.WA are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| SLV.WA | Selvita S.A.(you) | $132M | 40 | Hold |
| SCP.WA | Scope Fluidics S.A. | $116M | 11 | Strong Sell |
| VOX.WA | Voxel S.A. | $374M | 88 | Strong Buy |
| DIA.WA | Diagnostyka S.A. | $1.5B | 81 | Strong Buy |
| CLN.WA | Celon Pharma S.A. | $231M | 46 | Hold |
| BIO.WA | BIOTON S.A. | $87M | 51 | Hold |
| ICE.WA | Medinice S.A. | $200M | 25 | Sell |
| BCX.WA | Bioceltix S.A. | $118M | 18 | Strong Sell |
| MDG.WA | Medicalgorithmics S.A. | $75M | 16 | Strong Sell |
| MRC.WA | Mercator Medical S.A. | $143M | 73 | Buy |
Peer medians: ROE -19.0% · P/E 17.0x · Gross margin 30.1%